Q4 2020

Filed Mar 24, 2021 · 10-K · 83 days after period end · 0001826466-21-000075

Q4 2020 · 10-K

derived · Computed from the longer spans the company filed.

Revenue—

Net income—

EPS, diluted—Not derived. Share counts vary by quarter.

Operating Cash Flowderived-$5,747—

Same quarter

no prior Q4 2019 on file

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

ended Dec 31, 2020 · filed Mar 24, 2021 · 83 d after period end

Nika Pharmaceuticals, Inc · CIK 1145604 · Engraved from SEC EDGAR